Related Experiment Video
Updated: Aug 11, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
[Infants of diabetic mothers (IDM). II -- Fibronectin and perinatal morbidity]
G Martín Carballo1, R Codoceo Alquila, G Fernández Cano
1Servicio de Endocrinología, Hospital Infantil La Paz, Madrid.
Insights
Fibronectin levels in umbilical cord blood do not differ between infants of diabetic mothers and healthy newborns. Therefore, fibronectin is not a useful marker for evaluating perinatal complications in these infants.
Area of Science:
- Neonatal research
- Endocrinology
- Biochemistry
Background:
- Maternal diabetes mellitus can lead to adverse perinatal outcomes.
- Infants of diabetic mothers (IDM) are at increased risk for various complications.
- Biomarkers are needed to assess perinatal health in IDM.
Purpose of the Study:
- To measure fibronectin levels in the umbilical cord blood of IDM.
- To investigate the correlation between fibronectin levels and perinatal pathology in IDM.
Main Methods:
- Prospective study design.
- Inclusion of 58 IDM and 58 control newborns.
- Measurement of fibronectin levels in umbilical cord blood.
Main Results:
- No significant difference in fibronectin levels was observed between IDM and control groups.
- No sex-based differences in fibronectin levels were found.
- Higher perinatal morbidity was noted in the IDM group, but fibronectin levels did not correlate with these pathologies.
Conclusions:
- Fibronectin levels in umbilical cord blood are not a reliable indicator for perinatal evaluation in infants of diabetic mothers.
- Further research may be needed to identify effective biomarkers for IDM complications.
Objective:
The objective of this study was to determine fibronectin levels in umbilical cord blood of infants of diabetic mothers (IDM) and evaluate a possible correlation with perinatal pathology.
Patients And Methods:
A prospective study of 58 IDM (33 males and 25 females) and 58 control newborns (NB) (33 males and 25 females) was carried out.
Results:
There were no differences in fibronectin levels between the two groups nor between the sexes. Perinatal morbidity was higher in the IDM group, but there was no correlation between fibronectin levels and the presence of perinatal pathology.
Conclusions:
Fibronectin levels are not useful in the perinatal evaluation of infants of diabetic mothers.
More Related Videos
08:50A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
Published on: June 24, 2020
08:53Generation of the Early-Gestational Maternal Immune Activation Mouse Model to Assess Prenatal Inflammation on Neurodevelopment
Published on: March 24, 2026
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetes Mellitus: Introduction
Type I Diabetes III: Clinical Manifestations
Diabetic Retinopathy